First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, which have shown a significant improvement in overall survival (OS) gaining approval in a first line setting. Efficacy and safety of first-line weekly chemotherapy, compared to 3-weeks treatment, was retrospectively evaluated in a frail patient population with R/M HNSCC with the aim to evaluate its role as part of a personalized first-line approach.
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era / Botticelli, Andrea; Pomati, Giulia; Cirillo, Alessio; Mammone, Giulia; Ciurluini, Fabio; Cerbelli, Bruna; Sciattella, Paolo; Ralli, Massimo; Romeo, Umberto; De Felice, Francesca; Catalano, Carlo; Vullo, Francesco; Della Monaca, Marco; Amirhassankhani, Sasan; Tomao, Silverio; Valentini, Valentino; De Vincentiis, Marco; Tombolini, Vincenzo; Della Rocca, Carlo; Polimeni, Antonella; di Gioia, Cira; Corsi, Alessandro; D'Amati, Giulia; Mezi, Silvia; Marchetti, Paolo. - In: JOURNAL OF TRANSLATIONAL MEDICINE. - ISSN 1479-5876. - 19:1(2021). [10.1186/s12967-021-02975-3]
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era
Botticelli, AndreaCo-primo
;Pomati, GiuliaCo-primo
;Cirillo, Alessio
;Mammone, Giulia;Cerbelli, Bruna;Sciattella, Paolo;Ralli, Massimo;Romeo, Umberto;De Felice, Francesca;Catalano, Carlo;Vullo, Francesco;Della Monaca, Marco;Tomao, Silverio;Valentini, Valentino;De Vincentiis, Marco;Tombolini, Vincenzo;Della Rocca, Carlo;Polimeni, Antonella;di Gioia, Cira;Corsi, Alessandro;D'Amati, Giulia;Mezi, SilviaCo-primo
;Marchetti, PaoloCo-primo
2021
Abstract
First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, which have shown a significant improvement in overall survival (OS) gaining approval in a first line setting. Efficacy and safety of first-line weekly chemotherapy, compared to 3-weeks treatment, was retrospectively evaluated in a frail patient population with R/M HNSCC with the aim to evaluate its role as part of a personalized first-line approach.| File | Dimensione | Formato | |
|---|---|---|---|
|
Botticelli_Weekly-chemotherapy_2021.pdf
accesso aperto
Note: https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-02975-3
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
776.52 kB
Formato
Adobe PDF
|
776.52 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
